9 of 10 patients at the highest dose remained free from peritoneal recurrence at 24 months at the recommended dose Oslo, Norway, 17 February 2026 – Oncoinvent, a biotech developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announced that it will present […]
Brings deep expertise in immunology, oncology and pharmacology with a strong track record of advancing innovative pipelines through discovery and translation into the clinic Reflects growing momentum at Nucleome following nomination of first preclinical development candidate for lead candidate NTP464, which is progressing towards IND enabling studies Oxford, UK, 16 February 2026 – Nucleome Therapeutics […]
Oslo, Norway, 16 February 2026: Oncoinvent ASA (ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, is pleased to invite investors, analysts, and stakeholders to a live webcast event at 9:30 AM CET on Thursday, 26 February 2026. Second half […]
Recognition of AmacaThera’s leadership and landmark agreement with Pacira BioSciences for its long‑acting, opioid‑sparing anesthetic in post‑operative pain management Progressing AMT-143 to Phase 2 clinical development in 2026 Toronto, Ontario – February 11, 2026 — AmacaThera, a leading developer of next-generation hydrogel-based drug delivery solutions that enable precise, tunable, and sustained release to improve a […]
· Strong Q4 with 76.0 MSEK in revenue, up 135% from Q4 2024. · Submission of Biologics License Application (BLA) for imlifidase for highly sensitized patients awaiting kidney transplantation. · Successfully completed a directed share issue raising 671.5 MSEK (~ $71.3M). Lund, Sweden, 11 February 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced its […]
